Dear Sir,I have read the article by Daw and Dau with great interest and I have to congratulate the authors. However, the most recent prevalence of hepatitis C among hemodialysis patients in Sudan is stated to be 8.5% [1]. This puts Sudan among the lowest Arab countries in terms of prevalence of hepatitis C among hemodialysis, a thing that might change your conclusions on speaking about the lowest prevalence among Arab countries.Authors mentioned that the risk factors are associated with hepatitis C virus contraction. Gasim et al. found that the duration of hemodialysis is significantly associated with HCV contraction [1] and this could be explained by the fact that this HCV infection is a sort of a nosocomial one.Among the Japanese, recent data discussing the seroprevalence of HCV antibodies found it to vary between 8.5 and 12.5% [2], a thing which might be different from what the authors have mentioned when they spoke about a prevalence of 1.2%.Furthermore, there is a concern that authors referred to the paper titled Epidemiology of Hepatitis B and Hepatitis C Virus Infections among Hemodialysis Patients in Khartoum, Sudan [1] wrongly in paragraph 13 lines 5 and 6 that it showed the main hepatitis C virus genotype to be 4 with the subtypes 4e, 4c, and 4d while the fact is that the study showed the epidemiology of hepatitis C among hemodialysis, patients without addressing the matter of genotypes whereas Mudawi et al. 2007 described the genotypes, among patients with hepatosplenic schistosomiasis [3]. Thus, Mudawi et al. is the suitable reference rather than the mentioned one, and you might cite Gasim et al. 2012 in the lines speaking about seroprevalence.I'm afraid that the references [46-48] were mismatched between the citation in the text and the references list; I would be very much grateful if these were checked.